Nearly one-third of patients who responded to a survey did not understand common skin cancer terms frequently used by ...
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders ...
For the last 20 years, the standard-of-care adjuvant treatment for resected pathologically defined high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) has been ...
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, ...
SIOUX FALLS, SD - January 23, 2026 - PRESSADVANTAGE - Vance Thompson Vision is drawing attention to its advanced ...
Despite decades of sun-smart education, the number of treatments for certain types of skin cancer is on the increase.
Experts review warning nail features, from inflammatory conditions to tumours, offering practical guidance on diagnosis and ...
BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...
As of Tuesday, January 13, Sensus Healthcare, Inc.’s SRTS share price has surged by 10.65%, which has investors questioning ...
Bouraïma, F. , Ametonou, C. , Agbokponto, A. , Hounlelou, V. and Flatin, M. (2026) Tracheotomy in an African Hospital Setting ...
BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction. BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for ...
Receiving a diagnosis of squamous cell carcinoma (SCC) can be an overwhelming experience, but it is important to remember ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results